Colorado researcher says people with PTSD are losing out on an effective treatment
A Boulder-based therapist is disappointed by the FDA's decision not to approve MDMA-assisted therapy for PTSD, despite a Phase III study showing 71% of participants no longer met PTSD criteria. The therapist argues the decision is a setback for PTSD sufferers, who often face severe symptoms and suicidal thoughts. The FDA's decision may be due to a lack of precedent for approving a therapy rather than just a drug.
Reference News
A Boulder-based therapist is disappointed by the FDA's decision not to approve MDMA-assisted therapy for PTSD, despite a Phase III study showing 71% of participants no longer met PTSD criteria. The therapist argues the decision is a setback for PTSD sufferers, who often face severe symptoms and suicidal thoughts. The FDA's decision may be due to a lack of precedent for approving a therapy rather than just a drug.